The Technical AnalystExchange: PNK Industry: Biotechnology
Cardax, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0000
America/New_York / 27 des 2023 @ 09:38
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0000 mill |
| EPS: | -1.290 |
| P/E: | 0 |
| Earnings Date: | May 17, 2024 |
| SharesOutstanding: | 4.00 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-05-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | n/a | n/a | |
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0011 - 0.0011 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2014-02-24 | Paulson Capital (delaware) Corp. | Buy | 500 000 | Common Stock |
| 2014-02-24 | Paulson Cardax Investments 1 Llc | Buy | 500 000 | Common Stock |
| 2014-02-07 | Paulson Capital (delaware) Corp. | Buy | 1 068 477 | Warrants (right to buy) |
| 2014-02-07 | Paulson Cardax Investments 1 Llc | Buy | 1 068 477 | Warrants (right to buy) |
| 2014-02-07 | Paulson Capital (delaware) Corp. | Buy | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 4 transactions |
| Buy: 3 136 954 | Sell: 0 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0000 (0.00% ) |
| Volume | 0.0000 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CDXI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CDXI
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.